Related Experiment Video
Updated: Jul 2, 2026
11:19
Pairwise Growth Competition Assay for Determining the Replication Fitness of Human Immunodeficiency Viruses
Published on: May 4, 2015
Comparison of two PCR-based human papillomavirus genotyping methods
Philip E Castle1, Carolina Porras, Wim G Quint
1Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd., Room 5004, EPS MSC 7234, Bethesda, MD 20892-7234. castlep@mail.nih.gov.
Journal of Clinical Microbiology
|August 22, 2008
Summary
Two human papillomavirus (HPV) genotyping methods, SPF10 and Linear Array (LA), showed comparable results for detecting HPV16 and HPV18, crucial for HPV vaccine efficacy trials.
Area of Science:
- Virology
- Molecular Biology
- Public Health
Background:
- Cervical cancer is a significant global health concern, primarily caused by persistent infection with high-risk human papillomavirus (HPV) genotypes.
- Prophylactic HPV vaccines targeting HPV16 and HPV18 have been developed, necessitating reliable methods to monitor vaccine efficacy and HPV genotype prevalence.
- Accurate HPV genotyping is essential for epidemiological studies and clinical trials evaluating vaccine impact.
Purpose of the Study:
- To compare the performance of two consensus primer PCR HPV genotyping methods, SPF10 and Linear Array (LA), for detecting individual and carcinogenic HPV genotypes.
- To assess the suitability of these methods for monitoring the impact of HPV16/18 vaccines in clinical trials.
Main Methods:
- The study utilized a stratified sample of cervical specimens from women in the NCI/Costa Rica HPV16/18 Vaccine Efficacy Trial.
- DNA was extracted and amplified using either the SPF10 method (targeting a 65-bp region of the HPV L1 gene) or the Linear Array (LA) method (targeting a 450-bp region of the HPV L1 gene).
- Genotyping was performed using reverse-line blot hybridization, with 25 genotypes detected by SPF10 and 37 by LA.
Main Results:
- Both methods showed high overall agreement (91.8%, kappa=0.82) for grouped detection of carcinogenic HPV genotypes, with no significant difference in overall detection rates (35.3% vs. 35.9%).
- The LA method detected more individual carcinogenic HPV genotypes per specimen than the SPF10 method (P < 0.001).
- When SPF10 included genotype-specific testing for HPV16 and HPV18 in ungenotyped positive samples, both methods demonstrated comparable detection of these two critical genotypes.
Conclusions:
- The Linear Array (LA) method and the SPF10 method, with added HPV16/18 genotype-specific testing, are comparable for detecting HPV16 and HPV18.
- Both validated HPV genotyping approaches are suitable for monitoring the impact of HPV16/18 vaccines in clinical trials.
- These findings support the use of standardized HPV genotyping techniques in vaccine efficacy studies.
